Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Accentuates The Positives Of Heart Failure Drug Entresto At ACC

Executive Summary

Clinicians hail the efficacy data behind the new therapy, but some say reimbursement requirements are too onerous, resulting in slow uptake.

Advertisement

Related Content

Novartis' Late Bloomer Entresto Leads Take-Off Of Heart Failure Market
Novartis Woos Payers With Data Showing Entresto Earns Its Keep
Tekturna’s Loss May Be Entresto’s Gain As Novartis Hopes For Change In The ATMOSPHERE
Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057566

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel